Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 20, Issue 5, 2014, Pages 946-951

  Park, K T ^a   Crandall, Wallace V ^b   Fridge, Jacqueline ^c   Leibowitz, Ian H ^d   Tsou, Marc ^e   Dykes, Dana M H ^f   Hoffenberg, Edward J ^g   Kappelman, Michael D ^h   Colletti, Richard B ⁱ  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Randall Children's Hospital   (United States)

^d INOVA FAIRFAX HOSPITAL FOR CHILDREN   (United States)

^e EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF VERMONT   (United States)

Author keywords

Adalimumab; Anti TNF agents; Biologics; Cost reduction; Cost effectiveness; Costs; Crohn's disease; Healthcare; Inflammatory bowel disease; Infliximab; Quality improvement; Ulcerative colitis

Indexed keywords

INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; COMBINATION CHEMOTHERAPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; DRUG USE; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE MUCOSA; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; TOTAL QUALITY MANAGEMENT; WOUND HEALING; ANTAGONISTS AND INHIBITORS; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE PLANNING; INFLAMMATORY BOWEL DISEASES; PATHOLOGY;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEALTH PLAN IMPLEMENTATION; HUMANS; INFLAMMATORY BOWEL DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84902159799     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000441349.40193.aa     Document Type: Article

References (82)

1. Smith M, Saunders R, Stuckhardt L, eds. Best Care at Lower Cost: The Path to Continuously Learning Health Care in America. Washington DC: National Academies Press; 2013.
2. Rubin DT, Colletti RB, Sharma BK, et al. Health plan paid costs and drivers of health care costs for patients with Crohn's disease insured at six different commercial health plans in the United States. Gastroenterol. 2013;144:S635.
3. Express Scripts. Available at: http://lab.express-scripts.com/ prescription-drugtrends/specialty-drug-spending-to-jump-67-by-2015/. Accessed November 21, 2013.
4. Hanauer SB, Feagan BG, Lichtenstein GR, et al; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
5. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
6. Colombel JF, Sandborn WJ, Reinisch W, et al; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
7. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
8. Afif W, Leighton JA, Hanauer SB, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. In flamm Bowel Dis. 2009;15: 1302-1307.
9. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333; quiz 591.
10. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239.
11. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
12. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829-838.
13. Oussalah A, Laclotte C, Chevaux JB, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther. 2008;28: 966-972.
14. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780-787.
15. Sandborn WJ, Feagan BG, Stoinov S, et al; PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357:228-238.
16. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al; PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357:239-250.
17. Sandborn WJ, Feagan BG, Fedorak RN, et al; Ustekinumab Crohn's Disease Study Group. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-tosevere Crohn's disease. Gastroenterology. 2008;135:1130-1141.
18. Sandborn WJ, Ghosh S, Panes J, et al; Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367:616-624.
19. Parikh A, Fox I, Leach T, et al. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. In flamm Bowel Dis. 2013;19:1691-1699.
20. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005;352:2499-2507.
21. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008;6:1370-1377.
22. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:96-109.
23. Sandborn WJ, Feagan BG, Marano C, et al; Pursuit-sc study Group. Subcutaneous golimumab induces clinical response and remission in patients with moderate to severe ulcerative colitis. Gastroenterology. 2014;146: 85-95.
24. Sandborn WJ, Feagan BG, Rutgeerts P, et al; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369:711-721.
25. Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699-710.
26. FDA. FDA News Release. Available at: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm352383.htm. Accessed November 21, 2013.
27. Emanuel EJ, Steinmetz A. Will physicians lead on controlling health care costs? JAMA. 2013;310:374-375.
28. Crandall W, Kappelman MD, Colletti RB, et al. Improve Care Now: the development of a pediatric inflammatory bowel disease improvement network. In flamm Bowel Dis. 2011;17:450-457.
29. Billett AL, Colletti RB, Mandel KE, et al. Exemplar pediatric collaborative improvement networks: achieving results. Pediatrics. 2013;131(suppl 4):S196-S203.
30. Crandall WV, Margolis PA, Kappelman MD, et al; Improve Care Now Collaborative. Improved outcomes in a quality improvement collaborative for pediatric inflammatory bowel disease. Pediatrics. 2012;129:e1030-e1041. doi: 10.1542/peds.2011-1700.
31. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004;126:1593-1610.
32. Denmark VK, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update. Expert Rev Clin Immunol. 2013;9:77-92.
33. Tang DH, Harrington AR, Lee JK, et al. A systematic review of economic studies on biological agents used to treat Crohn's disease. In flamm Bowel Dis. 2013;19:2673-2694.
34. Dulai PS, Siegel CA, Dubinsky MC. Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease. In flamm Bowel Dis. 2013;19:2927-2936.
35. Dave M, Loftus EV Jr. Mucosal healing in inflammatory bowel disease-a true paradigm of success? Gastroenterol Hepatol (N Y). 2012;8:29-38.
36. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a singlecentre cohort. Gut. 2009;58:492-500.
37. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006;63:433-442; quiz 464.
38. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-413.
39. Lindsay J, Punekar YS, Morris J, et al. Health-economic analysis: costeffectiveness of scheduled maintenance treatment with infliximab for Crohn's disease-modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther. 2008;28:76-87.
40. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet. 2002;359: 1541-1549.
41. Vermeire S, Noman M, van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-1231.
42. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008;53:1020-1024.
43. Lopez A, Billioud V, Peyrin-Biroulet C, et al. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. In flamm Bowel Dis. 2013;19:1528-1533.
44. Billioud V, Laharie D, Filippi J, et al. Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience. In flamm Bowel Dis. 2011;17:152-159. doi: 10.1002/ibd.21491.
45. Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2012;107:1474-1482.
46. Lahiff C, Safaie P, Awais A, et al. The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2013; 37:786-794.
47. Magro F, Langner C, Driessen A, et al; on behalf of the European Society of Pathology (ESP) and the European Crohn's and Colitis Organisation (ECCO). European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013;7:827-851.
48. Panaccione R, Colombel JF, Louis E, et al. Evolving definitions of remission in Crohn's disease. In flamm Bowel Dis. 2013;19:1645-1653.
49. Berrill JW, Green JT, Hood K, et al. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. Aliment Pharmacol Ther. 2013;38:44-51.
50. Centers for Medicare & Medicaid Services Medicare Fee-for-Service Payment. 2012. Available at: http://www.cms.gov/Medicare/Medicare.html. Accessed September 1, 2012.
51. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369.
52. Henderson P, Anderson NH, Wilson DC. The Diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. [published online ahead of print May 14, 2013]. doi: 10.1038/ajg.2013.131.
53. Yang Z, Clark N, Park KT. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease. Clin Gastroenterol Hepatol. [published online ahead of print July 21, 2013]. doi: 10.1016/j.cgh.2013.06.028.
54. Wu M, Sin A, Nishioka F, et al. Non-drug costs associated with outpatient infliximab administration in pediatric inflammatory bowel disease. In flamm Bowel Dis. 2013;19:1514-1517.
55. Neef HC, Riebschleger MP, Adler J. Meta-analysis: rapid infliximab infusions are safe. Aliment Pharmacol Ther. 2013;38:365-376.
56. Condino AA, Fidanza S, Hoffenberg EJ. A home infliximab infusion program. J Pediatr Gastroenterol Nutr. 2005;40:67-69.
57. Gies N, Kroeker KI, Wong K, et al. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther. 2010;32:522-528.
58. Osterman MT, Haynes K, Delzell E, et al. Comparative effectiveness of infliximab and adalimumab for Crohn's disease. Clin Gastroenterol Hepatol. [published online ahead of print June 28, 2013]. doi: 10.1016/j.cgh.2013.06.010.
59. 2004 Drug Topics. Red Book. Montvale, NJ: Medical Economics; 2004.
60. Bouguen G, Siproudhis L, Gizard E, et al. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab. Clin Gastroenterol Hepatol. 2013;11:975-981.e4.
61. Panaccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC SUCCESS trial. Paper presented at: ECCO-IBD; February 24-26, 2011; Dublin, Ireland.
62. Wang SL, Hauenstein S, Ohrmund L, et al. Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. J Pharm Biomed Anal. 2013;78-79:39-44.
63. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011; 305:1460-1468.
64. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348:601-608.
65. Rojas JR, Taylor RP, Cunningham MR, et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther. 2005;313:578-585.
66. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248-1254.
67. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2013. [published online ahead of print July 22, 2013]. doi: 10.1136/gutjnl-2013- 305279.
68. Prometheus. Notification of Patient Financial Responsibility for PROMETHEUS ® Anser" Testing. Available at: www.prometheuslabs.com/ Resources/Billing/Patient-Financial-Responsibility-for-Anser-IFX-and-ADA.pdf. Accessed December 18, 2013.
69. Velayos FS, Kahn JG, Sandborn WJ, et al. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol. 2013;11:654-666.
70. Allen PB, Peyrin-Biroulet L. Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol. 2013;29:397-404.
71. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61:1619-1635.
72. Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep. 2013;15:315.
73. Zallot C, Peyrin-Biroulet L. Clinical risk factors for complicated disease: how reliable are they? Dig Dis. 2012;30(suppl 3):67-72.
74. Castiglione F, Testa A, Rea M, et al. Transmural healing evaluated by bowel sonography in patients with Crohn's disease on maintenance treatment with biologics. In flamm Bowel Dis. 2013;19:1928-1934.
75. Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology. 2012;142:1102-1111.e2.
76. Adler J, Sandberg KC, Shpeen BH, et al. Variation in infliximab administration practices in the treatment of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013;57:35-38.
77. Gecse KB, Khanna R, van den Brink GR, et al. Biosimilars in IBD: hope or expectation? Gut. 2013;62:803-807.
78. Megerlin F, Lopert R, Taymor K, et al. Biosimilars and the European experience: implications for the United States. Health Aff (Millwood). 2013;32:1803-1810.
79. Rinaudo-Gaujous M, Paul S, Tedesco ED, et al. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases. Aliment Pharmacol Ther. 2013;38:914-924. doi: 10.1111/apt.12477.
80. Danese S, Gomollon F; Governing Board and Operational Board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis. 2013;7:586-589.
81. Express Scripts. Available at: http://lab.express-scripts.com/speciality- medications/the-250-billion-potential-of-biosimilars/. Accessed November 21, 2013.
82. Reuters. Available at: http://www.reuters.com/article/2013/09/10/us- celltrionhospira-europe-idUSBRE9890IX20130910. Accessed November 21, 2013.